Overview

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Phase:
Phase 1
Details
Lead Sponsor:
Vitreous -Retina- Macula Consultants of New York
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab